Welcome to our dedicated page for Pharming Group news (Ticker: PHGUF), a resource for investors and traders seeking the latest updates and insights on Pharming Group stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pharming Group's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pharming Group's position in the market.
Pharming Group N.V. has announced the enrollment of the first patient in its Phase III clinical trial (NCT05438407) for leniolisib, aimed at treating children with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare genetic disorder. The trial will assess leniolisib's safety, efficacy, and tolerance in approximately 15 children aged 4 to 11 years across the U.S., Europe, and Japan. Primary efficacy endpoints include reducing lymph node size and increasing naïve B cell counts after 12 weeks. A subsequent trial for younger children (aged 1-6) is planned for Q3 2023. Leniolisib has shown promise in prior studies, and regulatory reviews are ongoing for broader approval.
Pharming Group N.V. (PHAR, PHGUF) announced that the European Medicines Agency (EMA) has validated its Marketing Authorisation Application (MAA) for leniolisib, an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS). The MAA, submitted in October 2022, will undergo an accelerated assessment, reducing the review period from 210 to 150 days. Positive Phase II/III study results showed leniolisib effectively reduced lymph node size and increased naïve B cell percentage in patients. Marketing authorisation is expected in H1 2023.
FAQ
What is the current stock price of Pharming Group (PHGUF)?
What is the market cap of Pharming Group (PHGUF)?
